Lexun Wang
Overview
Explore the profile of Lexun Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liang M, Wang L, Wang W
Cell Signal
. 2023 May;
108:110707.
PMID: 37164143
Type 2 diabetes mellitus (T2DM) is associated with high rates of morbidity and mortality worldwide. Prostaglandin E (PGE) is a lipid signaling molecule that can ameliorate the symptoms of some...
12.
Wei Q, Deng Y, Yang Q, Zhan A, Wang L
Front Immunol
. 2023 Feb;
14:1084636.
PMID: 36814909
Macrophages have a wide variety of roles in physiological and pathological conditions, making them promising diagnostic and therapeutic targets in diseases, especially metabolic disorders, which have attracted considerable attention in...
13.
Wang W, Liang M, Wang L, Bei W, Rong X, Xu J, et al.
Biochem Pharmacol
. 2022 Dec;
207:115357.
PMID: 36455672
Atherosclerosis, a trigger of cardiovascular disease, poses grave threats to human health. Although atherosclerosis depends on lipid accumulation and vascular wall inflammation, abnormal phenotypic regulation of macrophages is considered the...
14.
Wang L, Feng J, Deng Y, Yang Q, Wei Q, Ye D, et al.
Research (Wash D C)
. 2022 Oct;
2022:9891689.
PMID: 36299447
CCAAT/enhancer-binding proteins (C/EBPs) are a family of at least six identified transcription factors that contain a highly conserved basic leucine zipper domain and interact selectively with duplex DNA to regulate...
15.
Chen X, Yin J, Zhong Q, Wang K, Zhang X, Liang M, et al.
J Ethnopharmacol
. 2022 Oct;
301:115791.
PMID: 36240976
Ethnopharmacological Relevance: Fufang-zhenzhu-tiaozhi formula (FTZ) is a patented preparation of traditional Chinese medicine that has been used to treat hyperglycemia and hyperlipidemia in the clinic for almost 10 years. Our...
16.
Wang L, Zhang D, Zhan W, Zeng Z, Yin J, Wang K, et al.
Biomed Pharmacother
. 2022 Oct;
156:113831.
PMID: 36228370
Background: Diabetes mellitus-related coronary heart disease (DM-CHD) is the most common cause of death in diabetic patients. Various studies have shown that Chinese medicine Fufang-Zhenzhu-Tiaozhi capsule (FTZ) has therapeutic effects...
17.
Xu S, Ye B, Li J, Dou Y, Yu Y, Feng Y, et al.
Front Pharmacol
. 2022 Sep;
13:973927.
PMID: 36046814
The global morbidity of obesity and type 2 diabetes mellitus (T2DM) has dramatically increased. Insulin resistance is the most important pathogenesis and therapeutic target of T2DM. The traditional Chinese medicine...
18.
Song L, Wang K, Yin J, Yang Y, Li B, Zhang D, et al.
Chin Med
. 2022 Aug;
17(1):102.
PMID: 36042482
Background: Renal injury is one of the common microvascular complications of diabetes, known as diabetic kidney disease (DKD) seriously threatening human health. Previous research has reported that the Chinese Medicine...
19.
Zhang Y, Sun M, Wang D, Hu Y, Wang R, Diao H, et al.
Biomed Pharmacother
. 2022 Feb;
148:112696.
PMID: 35183007
Background: Despite the fact that the initial hypertrophic response to ventricular pressure overload is thought to be compensatory, prolonged stress often leads to heart failure. Previous studies have shown that...
20.
Zhang Y, Wang Z, Lan D, Zhao J, Wang L, Shao X, et al.
Pharmacol Res
. 2022 Feb;
177:106124.
PMID: 35149188
Cardiac fibrosis is a pathological process of multiple cardiovascular diseases, which may lead to heart failure. Studies have shown that microRNAs (miRNAs) play critical roles in regulating mitophagy and cardiac...